BILAG Biologics Prospective Cohort: The Use of Novel Biological Therapies in the Treatment of Systemic Lupus Erythematosus (SLE).

Trial Profile

BILAG Biologics Prospective Cohort: The Use of Novel Biological Therapies in the Treatment of Systemic Lupus Erythematosus (SLE).

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 14 Jul 2016

At a glance

  • Drugs Azathioprine (Primary) ; Mycophenolate mofetil (Primary) ; Antirheumatics; Cyclophosphamide; Immunomodulators; Immunosuppressants
  • Indications Systemic lupus erythematosus
  • Focus Adverse reactions; Biomarker; Therapeutic Use
  • Acronyms BILAG-BR
  • Most Recent Events

    • 07 Dec 2015 Accrual to date is 109% according to United Kingdom Clinical Research Network.
    • 10 Nov 2015 Accrual to date is 108% according to United Kingdom Clinical Research Network.
    • 25 Oct 2015 Accrual to date is 107% according to United Kingdom Clinical Research Network.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top